About 88 results

ALLMedicine™ Schnitzler Syndrome Center

Research & Reviews  30 results

Rheumatic involvement and bone scan features in Schnitzler syndrome: initial and follow...
Arthritis Research & Therapy; Darrieutort-Laffite C, Ansquer C et. al.

Nov 19th, 2020 - To report on the characteristics and long-term course of rheumatic manifestations in Schnitzler syndrome (SchS). A retrospective cohort study of patients with SchS followed between 2000 and 2020. Inclusion criteria included a diagnosis of SchS (St...

A Chinese case series of Schnitzler syndrome and complete remission in one tocilizumab-...
Clinical Rheumatology; Yan R, Cao W et. al.

Jun 10th, 2020 - Schnitzler syndrome (SchS) is a rare acquired systemic autoinflammatory disease. The major clinical features of SchS are urticarial rash and monoclonal gammopathy, accompanied by fever, joint pain, and lymphadenopathy. There were few reports about...

Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic liter...
Seminars in Arthritis and Rheumatism; Betrains A, Staels F et. al.

Jun 5th, 2020 - Schnitzler syndrome is a rare autoinflammatory disorder characterized by chronic urticarial rash and a monoclonal gammopathy, accompanied by intermittent fever, bone pain, and arthralgia or arthritis. Canakinumab is a fully human monoclonal anti-i...

Images of the month 1: Schnitzler syndrome: an acquired autoinflammatory syndrome.
Clinical Medicine (London, England); Zampeli E, Marinos L et. al.

Mar 19th, 2020 - Images of the month 1: Schnitzler syndrome: an acquired autoinflammatory syndrome.|2020|Zampeli E,Marinos L,Karakatsanis SJ,|diagnosis,genetics,diagnosis,drug therapy,

Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome.
The Journal of Allergy and Clinical Immunology; Krause K, Bonnekoh H et. al.

Jan 15th, 2020 - Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome.|2020|Krause K,Bonnekoh H,Ellrich A,Tsianakas A,Wagner N,|

see more →

Clinicaltrials.gov  4 results

Ilaris (Canakinumab) in the Schnitzler Syndrome

Jul 4th, 2019 - Description of the study: Objectives: Primary objective: To evaluate if canakinumab 150mg every 8 weeks can induce and maintain clinical remission in patients with the Schnitzler syndrome. Secondary objectives: To test if canakinumab 150mg can ind...

Ilaris® Effects in Schnitzler Syndrome (ILESCH)

Jul 16th, 2018 - This is a multi-center double-blind placebo-controlled study to assess the efficacy and safety of canakinumab (trade name Ilaris®), a high-affinity monoclonal antibody that neutralizes IL-1β, in patients with Schnitzler syndrome. Efficacy is asses...

Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)

May 30th, 2012 - This is a single-center open label study of the IL-1 transfusion protein rilonacept in subjects with Muckle-Wells syndrome (MWS), or Schnitzler syndrome (SchS) in Germany. Prospective subjects will be recruited from a patient population previously...

Efficacy and Safety of Canakinumab in Schnitzler Syndrome

May 23rd, 2012 - More on Canakinumab: Canakinumab is a high-affinity human monoclonal anti-human interleukin-1β (IL-1β)antibody of the IgG1/k isotype), developed for the treatment of IL-1β driven inflammatory diseases. Canakinumab binds human IL-1β and functionall...

see more →

News  1 results

Successful Treatment of Schnitzler Syndrome With Canakinumab
Robbie Pesek, MD, Roger Fox, MD

Sep 3rd, 2014 - To the Editor: Schnitzler syndrome occurs with a triad of chronic urticaria, recurring fevers, and monoclonal gammopathy. It was recognized as a clinical entity in 1972; now nearly 200 patients are reported in the medical literature.

see more →